Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

On this episode of The D1Baseball Podcast, Mike Rooney, Aaron Fitt and David Seifert discuss several fast-rising prospects from the early part of the 2025 season.